Can a new vaccine shield teens from meningitis?
NCT ID NCT06700148
First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time
Summary
This trial is testing an experimental vaccine designed to protect against four strains of the bacteria that cause meningococcal meningitis, a serious infection of the brain and spinal cord. The study involves around 840 participants aged 7 to 17, who will receive either the new vaccine or a standard one. The goal is to see if the new vaccine safely triggers a strong immune response and offers lasting protection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ACYW135 meningococcal polysaccharide conjugate vaccine (CRM197 vector)
- What this could lead to
- If successful, this vaccine could offer broader, longer-lasting protection against meningococcal meningitis in children and teens, potentially reducing outbreaks.
- What could go wrong
- The trial is still in Phase 3, and results may not confirm superior protection. As with any vaccine, there is a risk of side effects, though the study is designed to monitor safety closely.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MENINGOCOCCAL MENINGITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dengfeng Center for Disease Control and Prevention
Dengfeng, China
-
Kaifeng Center for Disease Control and Prevention
Kaifeng, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.